Evidence map›Paper›PMID 38740628›Full record

Trial reportAIDS and behavior2024

History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-country Trial Comparing Placebo Douche, Suppository, and Insert Products.

Rebecca Giguere, Iván C Balán, Bryan A Kutner, Seul Ki Choi, Ryan Tingler, Sherri Johnson, Nicole Macagna, Jessica Webster, Al Liu, Suwat Chariyalertsak and 12 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rebecca GiguereDivision of Gender, Sexuality and Health, HIV Center for Clinical and Behavioral Research, New York State Psychiatric Institute and Columbia University, New York, NY, USA. rebecca.giguere@med.fsu.edu.ORCID http://orcid.org/0000-0002-6529-0550
Iván C BalánCenter for Translational Behavioral Science, College of Medicine, Florida State University, Tallahassee, FL, USA.
Bryan A KutnerDivision of Gender, Sexuality and Health, HIV Center for Clinical and Behavioral Research, New York State Psychiatric Institute and Columbia University, New York, NY, USA.
Seul Ki ChoiUniversity of Pennsylvania, Philadelphia, PA, USA.
Ryan TinglerUniversity of Pennsylvania, Philadelphia, PA, USA.
Sherri JohnsonFHI 360, Durham, NC, USA.
Nicole MacagnaFHI 360, Durham, NC, USA.
Jessica WebsterUniversity of Pennsylvania, Philadelphia, PA, USA.
Al LiuBridge HIV at the San Francisco Department of Public Health, San Francisco, CA, USA.
Suwat ChariyalertsakResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Craig HoesleyUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Pedro GonzalesIMPACTA Asociación Civil, Impacta Salud y Educación, San Miguel CES, Lima, Peru.
Ken HoUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Noel KayangeBlanytre CRS, Johns Hopkins University Research Project, Blantyre, Malawi.
Thesla Palanee-PhillipsWits RHI, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Elizabeth BrownStatistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jillian ZemanekStatistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cindy E JacobsonFHI 360, Durham, NC, USA.
Gustavo F DoncelCONRAD, Eastern Virginia Medical School, Norfolk, VA, USA.
Jeanna PiperDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
José A BauermeisterUniversity of Pennsylvania, Philadelphia, PA, USA.
MTN-035 Protocol Team

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MILTON L WAINBERG · 2003 to 2026
$48.2M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
San Francisco Vaccine and Prevention UnitU01AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI BUCHBINDER, SUSAN · 2007 to 2011
$7.3M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases UM1AI068615Division of Intramural Research, National Institute of Allergy and Infectious Diseases UM1AI106707Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases UM1AI068633NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI068633NIAID NIH HHS U01 AI069463NIAID NIH HHS U01 AI069496NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069518NIAID NIH HHS UM1 AI106707NIMH NIH HHS K23 MH124569NIMH NIH HHS K23MH124569NIMH NIH HHS P30 MH043520NIMH NIH HHS P30MH043520United States Agency for International Development AID-OAA-A-14-00010
6 · The paper itself

Abstract

The DESIRE Study (MTN-035) explored product preference among three placebo rectal microbicide (RM) formulations, a rectal douche (RD), a suppository, and an insert, among 210 sexually active transgender people and men who have sex with men in five counties: the United States, Peru, Thailand, South Africa, and Malawi. Participants used each product prior to receptive anal sex (RAS) for 1 month, following a randomly assigned sequence, then selected their preferred product via computer assisted self-interview. In-depth interviews examined reasons for preference. We compared product preference and prior product use by country to explore whether geographic location and experience with the similar products impacted preference. A majority in the United States (56%) and Peru (58%) and nearly half in South Africa (48%) preferred the douche. Most in Malawi (59%) preferred the suppository, while half in Thailand (50%) and nearly half in South Africa (47%) preferred the insert. Participants who preferred the douche described it as quick and easy, already routinized, and serving a dual purpose of cleansing and protecting. Those who preferred the insert found it small, portable, discreet, with quick dissolution. Those who preferred the suppository found the size and shape acceptable and liked the added lubrication it provided. Experience with product use varied by country. Participants with RD experience were significantly more likely to prefer the douche (p = 0.03). Diversifying availability of multiple RM dosage forms can increase uptake and improve HIV prevention efforts globally.

Indexed as

Administration, RectalHIV InfectionsHomosexuality, MaleSexual and Gender MinoritiesAdolescentAdultAnti-Infective AgentsDosage FormsFemaleHumansMalawiMalePatient PreferencePeruPlacebosSexual BehaviorAnti-Infective AgentsDosage FormsPlacebosSuppositoriesAcceptabilityHIV preventionMicrobicideSexual minority menTransgender

Identifiers

PMID38740628
PMCPMC11480948

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.